A convergent approach using two key intermediates, segment A [a
l-proline-l-α-hydroxy-β-homoarginine-d-phenylalanine (Pro-hArg-d-Phe)
tripeptide] and segment B [a vinylogous
l-tyrosine-l-2,3-diaminopropanoic acid (vTyr-Dpr) dipeptide], was
developed for the synthesis of cyclotheonamide B (Scheme ). The starting compound for the preparation of
the hArg moiety 7, the
predominant part of segment A, was
N
α-(benzyloxycarbonyl)-N
ω,N
ω‘-bis(tert-butyloxycarbonyl)-l-arginine methyl ester (15, Scheme 2), which was converted
into the aldehyde 16 and subsequently
homologated using [tris(methylthio)methyl]lithium as a
carboxylic acid anion equivalent. Coupling
with properly protected Pro and d-Phe derivatives gave
smoothly the desired Pro-hArg-d-Phe
tripeptide derivative 24. The key feature of segment B,
i.e., the l-tyrosine-derived
α,β-unsaturated
γ-amino acid 4, was prepared by a Wadsworth−Emmons
olefination of the aldehyde 29 (Scheme 3)
derived from N-(tert-butyloxycarbonyl),
O-tert-butyl-l-tyrosine methyl ester
(28). Selective
N-(tert-butyloxycarbonyl) removal in the presence of the aryl
tert-butyl ether present in the fully protected
segment B, i.e.,
32, was achieved by treatment
with trimethylsilyl triflate/2,6-lutidine to give vTyr-Dpr dipeptide derivative 34 in quantitative yield.
Coupling of the key intermediates 24 and
34
using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
tetrafluoroborate (TBTU) afforded the
protected linear pentapeptide 35 in high yield (Scheme 4).
Treatment of 35 with
Pd(PPh3)4/morpholine resulted in simultaneous removal of the C-terminal
allyl group and the N-terminal
allyloxycarbonyl group to yield 36. Ring closure was
effected under dilution conditions by treatment
with TBTU/1-hydroxybenzotriazole/4-(dimethylamino)pyridine and
gave the protected cyclopentapeptide 37 in 61% yield. Oxidation of the hydroxyl
group with Dess−Martin periodinane (24 h, 40
°C) in the presence of tert-butyl alcohol gave
38, which was then subjected to
O,N-deprotection
with trifluoroacetic acid/thioanisole. Subsequent HPLC
purification afforded cyclotheonamide B
in an overall yield of 1.8% in 17 steps.